Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients
Information source: The Cleveland Clinic
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Postoperative Kidney Injury
Intervention: human albumin 5% (Drug); HES 130/0.4 (Voluven) (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: The Cleveland Clinic Official(s) and/or principal investigator(s): Andra Duncan, M.D., Principal Investigator, Affiliation: The Cleveland Clinic
Overall contact: Andra Duncan, M.D., Phone: 216-445-2372, Email: duncana@ccf.org
Summary
The purpose of this study is to evaluate the safety of a standard volume replacement called
HES 130/0. 4 (Voluven) during surgery on recovery. HES 130/0. 4 (Voluven) may offer an
alternative to pure fluid replacement solutions that are associated with problems after
surgery including fluid overload and respiratory difficulties. The safety of HES 130/0. 4
(Voluven) will be evaluated by examining its effects on kidney function, and coagulation
parameters and platelet (part of the blood that help it clot) function.
Participants will be randomized (like flipping a coin) to receive one of two possible volume
replacements during surgery, if fluid volume decreases enough to need replacement with one
of the fluids. The two possible volume replacements are Voluven (a starch-containing fluid)
or human albumin 5% (a protein-containing solution).
To examine kidney function, urine will be-sampled when the participant is put under general
anesthesia, before surgical incision, within one hour of arrival to the ICU and 24 hours
after completion of surgery. Two tubes (2 teaspoons) of blood (from an already established
line) will be taken the morning of the surgery, within one hour of arrival to the ICU, 24
hours after surgery and every morning during the participants postoperative ICU stay.
Additionally, health and recovery information will be recorded from the participant's
medical record. We will phone participants around 90 days and one year after surgery to ask
a few questions about one's health and recovery. We will also record blood sample analysis
results from follow up appointments within the first year after surgery. If this analysis is
not conducted at the Cleveland Clinic, with permission, we will obtain the results from a
treating physician.
Clinical Details
Official title: A Randomized Controlled Investigation of the Effects of 6% Hydroxyethylstarch 130/0.4 (Voluven) on Renal Function in Patients Having Aortic Valve Replacement With or Without Coronary Artery Bypass Grafting
Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Urine neutrophil gelatinase-associated lipocalin (NGAL) [Time Frame: 24 hours after surgery] [Designated as safety issue: Yes]
Secondary outcome: coagulation parameters and measures of platelet aggregation
Eligibility
Minimum age: 40 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age 50 - 85 years old
- Scheduled for elective aortic valve replacement with or without coronary artery
bypass grafting with or without additional minor surgical procedure.
- Written, informed consent for participation in this investigation.
Exclusion Criteria:
- Patients with renal failure with oliguria or anuria not related to hypovolemia.
- Patients receiving dialysis.
- Patients with preoperative renal insufficiency (Creatinine > 1. 6 mg/dL)
- Anticipated deep hypothermic circulatory arrest
- Known hypersensitivity or allergy to hydroxyethyl starch or the excipients of
hydroxyethyl starch
- Clinical conditions with volume overload (e. g., patients in pulmonary edema or
congestive heart failure)
- Patients with severe hypernatremia or severe hyperchloremia
- Patients with intracranial bleeding
- Pregnant or breast feeding women
- Critically ill adult patients, including patients with sepsis, due to increased risk
of mortality and renal replacement therapy, (e. g. patients who are hospitalized in
the intensive care unit prior to surgery)
- Severe liver disease
- Pre-existing coagulation or bleeding disorders
- Any contraindications to proposed interventions.
Locations and Contacts
Andra Duncan, M.D., Phone: 216-445-2372, Email: duncana@ccf.org
Cleveland Clinic Foundation, Cleveland, Ohio 44195, United States; Recruiting Andra Duncan, M.D., Phone: 216-445-2372, Email: duncana@ccf.org Roberta Johnson, Phone: 216-444-9950, Email: johnsor13@ccf.org Andra Duncan, M.D., Principal Investigator
Additional Information
Starting date: March 2015
Last updated: March 10, 2015
|